Skip to content
Menu

Connect Biopharma Holdings Limited CNTB

Full chart Compare
Set alert

Price alert · CNTB

All alert types
0.59 USD -0.04 (-6.08%)

Regular-session close

0.58 -0.01 -1.69%

After hours · Nov 20, 7:25 PM ET

0.5897 Day range 0.6378
0.579 52-week range 3.69
YTD
-79.08%
1 year
-81.27%

5D -0.0600 (-8.82%)

0.55000.60000.65000.7000FriMonTueWedThu0.6201
Market cap
38.05M
Revenue (ttm)
24.12M
Profit margin
-88.66%
EPS (ttm)
-1.19
Shares out
55.25M
Forward P/E
-5.04
YTD return
-79.08%
1-year return
-81.27%
Volume
365.98K
Avg volume
3.99M
Open
0.62
Previous close
0.6282
Day's range
0.5897 – 0.6378
52-week range
0.579 – 3.69
Beta
-0.31
Price target
7.00 (+1086.4%)

Key statistics

50-day average
1.12
200-day average
1.34
Enterprise value
-57.37M
Price / sales
2.31
Price / book
0.50
Free cash flow
-17.08M
Total cash
110.24M
Total debt
325.00K
Return on equity
-17.92%
Short % of float
0.18%

Fundamental scorecard

4 of 25 checks passed on CNTB’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CNTB Revenue — quarterly 736.00K
CNTB Net income — quarterly -16.15M
CNTB EPS — quarterly -0.26

Earnings

CNTB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 30, 2023Dec 1, 2022-0.48———

Upgrades / downgrades

CNTB analyst upgrades and downgrades
DateFirmActionFromTo
Sep 6, 2024HC Wainwright & Co.reitBuyBuy
Jun 13, 2024HC Wainwright & Co.reitBuyBuy
Apr 17, 2024HC Wainwright & Co.mainBuyBuy
Mar 4, 2024HC Wainwright & Co.init—Buy
Sep 13, 2023Cantor FitzgeraldreitOverweightOverweight
Feb 8, 2023SVB Leerinkmain—Outperform

About Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on CNTB — it syncs with the Stock Master app.

Institution ownership

CNTB institution ownership
Holder% heldSharesValueReported
BML Capital Management, LLC3.79%2,093,2322.11MSep 29, 2024
O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC)0.92%510,701514.48KSep 29, 2024
Renaissance Technologies, LLC0.32%175,500176.80KSep 29, 2024
Callan Capital LLC0.08%41,82342.13KSep 29, 2024
Keudell/Morrison Wealth Management0.06%33,45033.70KSep 29, 2024
Royal Bank of Canada0.06%30,60030.83KSep 29, 2024

Fund ownership

CNTB fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.05%27,96128.17KOct 30, 2024